10.25.22
Booth # 4652
Gnosis by Lesaffre will debut a version of its MenaQ7 vitamin K2 as MK-7 branded ingredient delivered in a matrix-enhanced protective technology.
According to the ingredient supplier, dealing with moisture and mineral salts present complexities in preventing the degradation of vitamin K2, driving the need for a protective technology to shelter the menaquinone molecules during shelf life. The matrix, originally launched in 2021, is a proprietary technology that protects particles of MK-7 with no coating, additives, or additional ingredients, providing a less cumbersome and more predictable formulation process for K2 products.
“Stability is a constant issue facing commercial partners who desire to create complex vitamin K2 formulations. that process is now more efficient because the Matrix technology embeds the K2 as MK7 particles in the product, thus leading to faster market introductions,” said Xavier Berger, global market manager with Gnosis by Lesaffre. “Matrix was explicitly developed for Vitamin K2; it is not an adaptation of an existing technology previously utilized for other ingredients. Our team has worked extensively to ensure that our innovation was truly unique to the market, and, most importantly, that it would have a tremendous impact for those with a vision for what the market needs.”
The matrix enables cost-effective manufacturing, as improved stability and homogeneity reduce the need for overages, according to Gnosis by Lesaffre, and the short list of ingredients with no additives allows for clean labels.
“Gnosis by Lesaffre is a guarantor of quality in all that we do, which is why MenaQ7 is such an important piece of our portfolio,” said Marc Philouze, general manager. “The MenaQ7 brand carries a stellar reputation built upon an unprecedented body of clinical evidence and patents, produced to the highest quality standards. Applying the Matrix protective technology to MenaQ7 ensures a smoother process for formulators to bring any product concept they can conceive to life. More importantly, it ensures that consumers receive the clinically validated benefits they rightfully expect.”
Gnosis by Lesaffre will debut a version of its MenaQ7 vitamin K2 as MK-7 branded ingredient delivered in a matrix-enhanced protective technology.
According to the ingredient supplier, dealing with moisture and mineral salts present complexities in preventing the degradation of vitamin K2, driving the need for a protective technology to shelter the menaquinone molecules during shelf life. The matrix, originally launched in 2021, is a proprietary technology that protects particles of MK-7 with no coating, additives, or additional ingredients, providing a less cumbersome and more predictable formulation process for K2 products.
“Stability is a constant issue facing commercial partners who desire to create complex vitamin K2 formulations. that process is now more efficient because the Matrix technology embeds the K2 as MK7 particles in the product, thus leading to faster market introductions,” said Xavier Berger, global market manager with Gnosis by Lesaffre. “Matrix was explicitly developed for Vitamin K2; it is not an adaptation of an existing technology previously utilized for other ingredients. Our team has worked extensively to ensure that our innovation was truly unique to the market, and, most importantly, that it would have a tremendous impact for those with a vision for what the market needs.”
The matrix enables cost-effective manufacturing, as improved stability and homogeneity reduce the need for overages, according to Gnosis by Lesaffre, and the short list of ingredients with no additives allows for clean labels.
“Gnosis by Lesaffre is a guarantor of quality in all that we do, which is why MenaQ7 is such an important piece of our portfolio,” said Marc Philouze, general manager. “The MenaQ7 brand carries a stellar reputation built upon an unprecedented body of clinical evidence and patents, produced to the highest quality standards. Applying the Matrix protective technology to MenaQ7 ensures a smoother process for formulators to bring any product concept they can conceive to life. More importantly, it ensures that consumers receive the clinically validated benefits they rightfully expect.”
